Obez hastalarda kısa dönem (1 aylık) orlistat tedavisinin plazma lipid düzeylerine etkisi

Year 2006, Volume: 13 Issue: 3, 1 - 3, 21.04.2009

Ercan Varol , Mehmet Şahin S.murat Aslan Mehmet Özaydın Ahmet Altınbaş

Abstract

SüleymanDemirel Üniversitesi
TIP FAKÜLTESİ DERGİSİ: 2006 Eylül; 13(3)


Obez hastalarda kısa dönem (1 aylık) orlistat tedavisinin

plazma lipid düzeylerine etkisi



Ercan Varol, Mehmet Şahin, S Murat Aslan, Mehmet Özaydın, Ahmet Altınbaş



Özet


Obez hastalarda kısa dönem (1 aylık) orlistat tedavisinin plazma lipid düzeylerine etkisi



Kısa dönem, 1 aylık orlistat tedavisinin lipid profili üzerine etkisini araştırmak. Onüç obez hastada düşük kalorili diyete ilave olarak günde 3 kez 120 mg orlistat verildi. Başlangıç ve 1 ay sonraki plazma lipid düzeylerine bakıldı. Trigliserid (TG) seviyesi 169.9 ± 62.7 mg/dl den 156.6 ± 60.4 mg/dl'ye (p<0.05), düşük dansiteli lipoprotein kolesterol (LDL-K) seviyesi 137.7 ± 17.5 mg/dl den 136.1 ± 17.2 mg/dl'ye (p<0.05) ve total kolesterol (TK) seviyesi 222.1 ± 47.3 mg/dl den 220.8 ± 47.6 mg/dl seviyesine düştü (p<0.05). Azalmalar istatistiksel açıdan anlamlı idi. Yüksek dansiteli lipoprotein kolesterol (HDL-K) seviyesindeki artış anlamlı değildi (36.5 ± 2.7 mg/dl den 36.9 ± 2.4 mg/dl' ye; p=0.09). Orlistat kilo verdirici etkisinden bağımsız olarak 1 aylık kısa dönemde lipid profili üzerine olumlu etkiye sahiptir.


Anahtar kelımeler: Obezite, Orlistat, Kolesterol, Trigliserid


Abstract


Effect of short term (1 month) orlistat treatment on plasma lipid levels ın obese patients



The aim of the study is to investigate the effect of a short term 1–month orlistat treatment on lipid profile in obese patients. Orlistat was administered three times 120 mg in a day in conjunction with a reduced calorie diet in 13 obese patients. Plasma lipid levels were determined at beginning and 1 month later. The triglyceride level decreased from 169.9 ± 62.7 mg/dl to 156.6 ± 60.4 mg/dl (p<0.05), low density lipoprotein cholesterol level decreased from 137.7 ± 17.5 mg/dl to 136.1 ± 17.2 mg/dl (p<0.05) and total cholesterol level decreased from 222.1 ± 47.3 mg/dl to 220.8 ± 47.6 mg/dl (p<0.05). The changes were statistically significant. The increase in high density lipoprotein cholesterol levels was not statistically significant (36.5 ± 2.7 mg/dl to 36.9 ± 2.4 mg/dl; p=0.09). Orlistat has a beneficial effect on lipid profiles in 1 month short term period in obese patients regardless of weight loss.



Key words: Obesity, Orlistat, Cholesterol, Triglyceride

Keywords

Obezite, Orlistat, Kolesterol, Trigliserid

References

• Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB & Patel IH Retrospective population- based analysis of the dose response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56: 82–85.
• Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disorder 1997; 21 (suppl.3): S12–S23
• Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP et al. Randomized placebo – controlled trial of orlistat of weight loss and prevention of weight regain in obese patiants. Lancet 1998; 352; 167 – 172
• Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999; 281: 235–242.
• Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance and impaired cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000; 8: 49–61.
• Kelley DE, Bray GA, Pi-Sunyer. Clinical efficacy of orlistat therapy in owerweight and obese patients with insulin treated-type 2 diabetes: a 1-year randomized controlled trial . Diabetes Care 2002; 25: 1033-41.
• Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, double-blind, placebo-controlled comparison of action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profili, in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Therapeutics 2003; 25: 1107-22.
• Muls E, Kolanowski J, Scheen E, Van Gaal L. The effects of orlistat on weight and serum lipids in obese patients with hypercholestrolemia: a randomized, double blind, placebo controlled, multicentre study. Int J Obes Relat Metab Disord 2001; 25: 1713-21
• Lucas CP, Boldrin MN, Reaven GM. Effect of orlistat added to diet ( 30 % of calories from fat) on plasma lipids, glucose and insulin in obese patients with hypercholesterolemia. Am J Cardiol 2003; 91: 961–964.
• Bloch KV, Salles KF, Muxfeldt ES, da Rocha Nogueria A. Orlistat in hypertensive overweight / obese patients: results of a randomized clinical trial. J Hypertens 2003; 21(11): 2159-65.
• van Greevenbroek MM, de Bruin TW. Chylomicron synthesis by intestinal cells in vitro and in vivo. Atherosclerosis 1998; 141(suppl 1): S9–S16.
• Wierzbicki AS, Reynolds TM, Crook MA. Usefulness of orlistat in the treatment of severe hypertriglyceridemia. Am J Cardiol 2002; 89: 229–31.
• Mittendorfer B, Ostlund RE, Patterson BW, Klein S. Orlistat inhibits dietary cholesterol absorbtion. Obes Res 2001; 9: 599-604
• Hutton B, Ferguson D. Changes in body weigth and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systemic rewiew of randomized clinical trials. Am J Clin Nutr 2004; 80: 1461-8